Pfizer Extends Vyndamax Exclusivity To 2031 And Eases Patent Cliff Risk

Simply Wall St.01:05

Pfizer (NYSE:PFE) has reached settlements with three generic manufacturers that extend US exclusivity for VYNDAMAX (tafamidis) until 2031. The agreements remove a near term patent cliff risk that had ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632650902?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137","is_english":true,"pubTime":"2026-05-01 01:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632650902","market":"us","top_or_hot":-1,"title":"Pfizer Extends Vyndamax Exclusivity To 2031 And Eases Patent Cliff Risk","media":"Simply Wall St.","content":"<div>\n<p>Pfizer (NYSE:PFE) has reached settlements with three generic manufacturers that extend US exclusivity for VYNDAMAX (tafamidis) until 2031. The agreements remove a near term patent cliff risk that had ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-extends-vyndamax-exclusivity-to-2031-and-eases-patent\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Extends Vyndamax Exclusivity To 2031 And Eases Patent Cliff Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Extends Vyndamax Exclusivity To 2031 And Eases Patent Cliff Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-01 01:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-extends-vyndamax-exclusivity-to-2031-and-eases-patent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) has reached settlements with three generic manufacturers that extend US exclusivity for VYNDAMAX (tafamidis) until 2031. The agreements remove a near term patent cliff risk that had ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-extends-vyndamax-exclusivity-to-2031-and-eases-patent\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-extends-vyndamax-exclusivity-to-2031-and-eases-patent","article_id":"2632650902","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-extends-vyndamax-exclusivity-to-2031-and-eases-patent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632650902","pubTimestamp":1777568748,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pfizer (NYSE:PFE) has reached settlements with three generic manufacturers that extend US exclusivity for VYNDAMAX (tafamidis) until 2031.\nThe agreements remove a near term patent cliff risk that had been expected around 2029 for this major cardiovascular drug.\nVYNDAMAX remains the leading approved therapy in the US for transthyretin mediated amyloidosis, a serious and often underdiagnosed condition.\n\nFor investors watching NYSE:PFE, this development centers on one of Pfizer’s key specialty...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4534":"瑞士信贷持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4550":"红杉资本持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4568":"美国抗疫概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","PFE":"辉瑞","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4581":"高盛持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4599":"减肥药","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"translate_title":"辉瑞将Vyndamax独家经营权延长至2031年并缓解专利悬崖风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"Pfizer (NYSE:PFE) has reached settlements with three generic manufacturers that extend US exclusivity for VYNDAMAX (tafamidis) until 2031. The agreements remove a near term patent cliff risk that had been expected around 2029 for this major cardiovascular drug. VYNDAMAX remains the leading approved therapy in the US for transthyretin mediated amyloidosis, a serious and often underdiagnosed condition.  For investors watching NYSE:PFE, this development centers on one of Pfizer’s key specialty medicines rather than its larger primary care portfolio. Cardiovascular and rare disease treatments have become an important piece of the company’s mix as patent timelines and competition shape branded drug lifecycles across the sector. Extended exclusivity on a high value product can influence how Pfizer allocates resources between established brands and earlier stage assets. With VYNDAMAX patent protection now expected to run through at least mid 2031, Pfizer has a clearer line of sight on this product’s role in its medium term plan. That visibility can feed into decisions on R&D, business development, and capital return policies, which are closely watched by shareholders assessing the company’s risk and reward profile. Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer. NYSE:PFE 1-Year Stock Price Chart Is Pfizer's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. The VYNDAMAX settlements give Pfizer more breathing room on a product that already holds about 75% of prescription volume in transthyretin-mediated amyloidosis. By pushing the effective US patent date to June 1, 2031, management now has a longer period where this therapy is expected to face limited generic pressure, with revenues described as relatively stable from 2028 through mid 2031. For a company dealing with other patent expiries, including Eliquis and oncology brands, locking in a protected cardiology revenue stream can make cash flow planning and capital allocation more predictable. It also matters competitively, because rivals such as Alnylam, AstraZeneca, BridgeBio and Ionis are active in cardiomyopathy and rare disease. Holding the market-leading oral option for longer can influence how those companies think about pricing, trial design and positioning. On the flip side, the settlements do not remove all legal uncertainty, because the extended date is still subject to the outcome of other litigation, and pricing pressure from US policy changes remains a separate risk even where exclusivity is intact. AdvertisementHow This Fits Into The Pfizer Narrative  The longer VYNDAMAX runway supports the narrative that a larger share of Pfizer’s portfolio is shifting toward higher value specialty and rare disease medicines that can help offset revenue pressure from patent expiries elsewhere. The focus on patent settlements also highlights the narrative risk that regulation and competition around drug pricing and access could still pressure margins, even when exclusivity is extended. The commentary in the narrative on competitive threats in cardiology and rare disease may not fully reflect that VYNDAMAX now has a clearer exclusivity horizon through 2031, which may change how investors weigh ATTR-CM contributions versus other at-risk products.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Pfizer to help decide what it is worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Analysts have flagged that Pfizer’s debt is not well covered by operating cash flow, so any future legal or pricing pressure on VYNDAMAX could matter more if it constrains a key cash generator. ⚠️ The VYNDAMAX exclusivity date remains subject to other litigation and ongoing US policy discussions on drug pricing, which could affect both duration of exclusivity and effective net pricing. 🎁 Trading at what Simply Wall St describes as roughly 59.5% below an intrinsic value estimate, a more visible revenue path from VYNDAMAX to 2031 adds another data point for investors weighing risk and reward. 🎁 Stabilising an important cardiovascular product through settlements can help support Pfizer’s ability to fund late stage obesity, oncology and vaccine programs while continuing its long dividend record.  What To Watch Going Forward From here, focus on how Pfizer talks about ATTR-CM in guidance and filings, especially any updated revenue commentary for VYNDAMAX from 2028 to 2031, and disclosures on remaining litigation. Watch for regulatory or reimbursement changes that could affect pricing for high cost rare disease treatments, as well as competitive readouts from Alnylam, AstraZeneca, BridgeBio and Ionis in cardiomyopathy or amyloidosis. Investors should also track how this more stable VYNDAMAX outlook is balanced against the approaching patent cliffs on other major drugs and any shifts in dividend or debt priorities. To stay informed on how the latest news affects the investment narrative for Pfizer, visit the\ncommunity page for Pfizer to follow updates on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632650902","isCrawlerRequest":true}